Summary & Overview
CPT 0121U: Flow Adhesion Assay (FAB‑V) for Sickle Cell Disease
CPT code 0121U designates a Proprietary Laboratory Analyses (PLA) test: the Flow Adhesion of Whole Blood on VCAM–1 (FAB–V) assay from Functional Fluidics. The assay measures whole‑blood cell adhesion to VCAM‑1 under flow conditions to assess the effects of therapies aimed at preventing cell adhesion in patients with sickle cell disease. As a PLA code, 0121U is unique to a specific manufacturer and lab, which affects reporting, billing clarity, and payer review processes nationally.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for use in sickle cell disease, what PLA designation implies for coding and documentation, and the typical laboratory setting where the test is performed. The publication also covers payer coverage contours and benchmarking considerations, policy implications for proprietary assays, and documentation elements payers commonly review. Data not available in the input for associated taxonomies, ICD‑10 diagnoses, and related codes are noted where relevant.
Billing Code Overview
CPT code 0121U is a Proprietary Laboratory Analyses (PLA) code for the Flow Adhesion of Whole Blood on VCAM–1 (FAB–V) test from Functional Fluidics. This test is a flow–based cell adhesion assay performed on whole blood to assess the effects of drugs to prevent cell adhesion in patients with sickle cell disease.
-
Service type: Laboratory diagnostic test (proprietary flow‑based cell adhesion assay)
-
Typical site of service: Clinical laboratory or specialized diagnostics laboratory performing proprietary PLA testing
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adolescent or adult with sickle cell disease referred by a hematologist to assess cellular adhesion response to anti-adhesion or anti-inflammatory therapies. The patient presents for a focused blood-based laboratory evaluation to measure Flow Adhesion of Whole Blood on VCAM–1 (FAB–V) to quantify leukocyte and sickled red cell adhesion under flow conditions. The clinical workflow: outpatient hematology orders the proprietary 0121U PLA test when evaluating baseline adhesion phenotype, monitoring response to vaso-occlusive crisis prophylaxis, or assessing pharmacodynamic effect of agents (for example, P‑selectin or VCAM–1 targeted therapies). On the day of service, a certified phlebotomist collects a whole blood specimen per Functional Fluidics kit instructions; the specimen is transported at controlled temperature to the performing laboratory. The lab performs the flow‑based cell adhesion assay and issues a report with quantitative adhesion metrics and interpretation for the ordering hematologist. Results inform clinical decisions about therapy initiation, dose adjustments, or continued monitoring for patients with sickle cell disease experiencing recurrent vaso‑occlusive events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation component if separated from the technical component by contract or billing arrangement |